BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7625456)

  • 1. Alzheimer's dementia.
    Chase TN; Tamminga CA
    Am J Psychiatry; 1995 Aug; 152(8):1110. PubMed ID: 7625456
    [No Abstract]   [Full Text] [Related]  

  • 2. Altered cerebral energy metabolism in Alzheimer's disease: a PET study.
    Fukuyama H; Ogawa M; Yamauchi H; Yamaguchi S; Kimura J; Yonekura Y; Konishi J
    J Nucl Med; 1994 Jan; 35(1):1-6. PubMed ID: 8271029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography in patients with clinically diagnosed Alzheimer's disease.
    McGeer PL; Kamo H; Harrop R; Li DK; Tuokko H; McGeer EG; Adam MJ; Ammann W; Beattie BL; Calne DB
    CMAJ; 1986 Mar; 134(6):597-607. PubMed ID: 3512063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease: focal cortical changes shown by positron emission tomography.
    Foster NL; Chase TN; Fedio P; Patronas NJ; Brooks RA; Di Chiro G
    Neurology; 1983 Aug; 33(8):961-5. PubMed ID: 6603596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preferential metabolic involvement of visual cortical areas in a subtype of Alzheimer's disease: clinical implications.
    Pietrini P; Furey ML; Graff-Radford N; Freo U; Alexander GE; Grady CL; Dani A; Mentis MJ; Schapiro MB
    Am J Psychiatry; 1996 Oct; 153(10):1261-8. PubMed ID: 8831432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cortical abnormalities in Alzheimer's disease.
    Foster NL; Chase TN; Mansi L; Brooks R; Fedio P; Patronas NJ; Di Chiro G
    Ann Neurol; 1984 Dec; 16(6):649-54. PubMed ID: 6335378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gender differences in cortical glucose metabolism in Alzheimer's disease and normal aging.
    Siegel BV; Shihabuddin L; Buchsbaum MS; Starr A; Haier RJ; Valladares Neto DC
    J Neuropsychiatry Clin Neurosci; 1996; 8(2):211-4. PubMed ID: 9081560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer's disease.
    Sultzer DL; Mahler ME; Mandelkern MA; Cummings JL; Van Gorp WG; Hinkin CH; Berisford MA
    J Neuropsychiatry Clin Neurosci; 1995; 7(4):476-84. PubMed ID: 8555751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinations of cerebral glucose utilization in dementia using positron emission tomography.
    Kuhl DE; Metter EJ; Riege WH; Hawkins RA
    Dan Med Bull; 1985 Feb; 32 Suppl 1():51-5. PubMed ID: 3872772
    [No Abstract]   [Full Text] [Related]  

  • 10. The fluorodeoxyglucose 18F scan in Alzheimer's disease and multi-infarct dementia.
    Benson DF; Kuhl DE; Hawkins RA; Phelps ME; Cummings JL; Tsai SY
    Arch Neurol; 1983 Nov; 40(12):711-4. PubMed ID: 6605139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET.
    Piert M; Koeppe RA; Giordani B; Berent S; Kuhl DE
    J Nucl Med; 1996 Feb; 37(2):201-8. PubMed ID: 8667045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diminished glucose transport in Alzheimer's disease: dynamic PET studies.
    Jagust WJ; Seab JP; Huesman RH; Valk PE; Mathis CA; Reed BR; Coxson PG; Budinger TF
    J Cereb Blood Flow Metab; 1991 Mar; 11(2):323-30. PubMed ID: 1997504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's disease: anterior-posterior and lateral hemispheric alterations in cortical glucose utilization.
    Friedland RP; Budinger TF; Koss E; Ober BA
    Neurosci Lett; 1985 Feb; 53(3):235-40. PubMed ID: 3872424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive and cerebral metabolic function in early and advanced Alzheimer's disease.
    Chase TN; Foster NL; Fedio P; Mansi L; Brooks R; Kessler R; Di Chiro G
    Monogr Neural Sci; 1984; 11():176-9. PubMed ID: 6610824
    [No Abstract]   [Full Text] [Related]  

  • 15. A comparison of FDG PET and IQNB SPECT in normal subjects and in patients with dementia.
    Weinberger DR; Jones D; Reba RC; Mann U; Coppola R; Gibson R; Gorey J; Braun A; Chase TN
    J Neuropsychiatry Clin Neurosci; 1992; 4(3):239-48. PubMed ID: 1498576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-2-deoxy-2-fluoro-D-glucose as a tracer in the positron emission tomographic study of senile dementia.
    Farkas T; Ferris SH; Wolf AP; De Leon MJ; Christman DR; Reisberg B; Alavi A; Fowler JS; George AE; Reivich M
    Am J Psychiatry; 1982 Mar; 139(3):352-3. PubMed ID: 6977276
    [No Abstract]   [Full Text] [Related]  

  • 17. Cerebral mapping of apraxia in Alzheimer's disease by positron emission tomography.
    Foster NL; Chase TN; Patronas NJ; Gillespie MM; Fedio P
    Ann Neurol; 1986 Feb; 19(2):139-43. PubMed ID: 3485952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]fluorodeoxyglucose.
    Friedland RP; Budinger TF; Ganz E; Yano Y; Mathis CA; Koss B; Ober BA; Huesman RH; Derenzo SE
    J Comput Assist Tomogr; 1983 Aug; 7(4):590-8. PubMed ID: 6602819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.
    Alexander GE; Chen K; Pietrini P; Rapoport SI; Reiman EM
    Am J Psychiatry; 2002 May; 159(5):738-45. PubMed ID: 11986126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of cerebral glucose utilization in dementia.
    Matsuzawa T; Matsui H; Meguro K; Ueda M; Yamada K; Yamaguchi T; Itoh M; Hatazawa J; Kinomura S
    Sci Rep Res Inst Tohoku Univ Med; 1990 Dec; 37(1-4):11-21. PubMed ID: 2103655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.